Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies

References

• National Institutes of Health. Cancer Stat Facts: Myeloma. [cited 2020 May 5]. Available from https://seer.cancer.gov/statfacts/html/mulmy.html.
   Google Scholar
• Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematol Am Soc Hematol Educ Program. 2017;2017(1):498–507.
   PubMedGoogle Scholar
• Branagan A, Lei M, Lou U, et al. Current treatment strategies for multiple myeloma. JCO Oncol Pract. 2020;16(1):5–14.
   PubMedGoogle Scholar
• Voorhees PM, Usmani SZ. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. Clin Adv Hematol Oncol. 2016;14(9):719–728.
   PubMedGoogle Scholar
• Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017;281(4):365–382.
   PubMed Web of Science ®Google Scholar
• Kyprolis® (carfilzomib). Full prescribing information. Thousand Oaks, CA: Amgen Inc., 2020.
   Google Scholar
• Kyprolis (carfilzomib). Summary of product characteristics. Breda, Netherlands: Amgen Europe, 2018.
   Google Scholar
• Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197.
   PubMed Web of Science ®Google Scholar
• Jasielec JK, Kubicki T, Raje N, et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020;136(22):2513–2523.
   PubMed Web of Science ®Google Scholar
• Roussel M, Lauwers-Cances V, Wuilleme S, et al. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results. Blood. 2021;138(2):113–121.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Dytfeld D, Griffith KA, et al. Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up. J Clin Oncol. 2013;31(Supplement 15):8543–8543.
   Web of Science ®Google Scholar
• Kazandjian D, Korde N, Mailankody S, et al. Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial. JAMA Oncol. 2018;4(12):1781–1783.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Korde N, Mailankody S, et al. A phase 2 study of carfilzomib, lenalidomide, and dexamethasone with lenalidomide maintenance (KRd-r) in newly diagnosed multiple myeloma (NDMM): sustained long term deep remissions and prolonged progression-free duration regardless of age or cytogenetic risk after 5 years of follow up. Blood. 2018;132(Supplement 1):1957–1957.
   Google Scholar
• Kumar SK, Callander NS, Baljevic M NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Multiple Myeloma, Version 5.2022. [cited 2022 May 5]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
   Google Scholar
• Kumar SK, Jacobus SJ, Cohen AD, et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020;21(10):1317–1330.
   PubMed Web of Science ®Google Scholar
• Gay F, Musto P, Rota-Scalabrini D, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22(12):1705–1720.
   PubMed Web of Science ®Google Scholar
• International Myeloma Foundation. International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. [cited 2020 May 5]. Available from https://www.myeloma.org/resource-library/international-myeloma-working-group-imwg-uniform-response-criteria-multiple.
   Google Scholar
• Chng WJ, Goldschmidt H, Dimopoulos MA, et al. Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia. 2017;31(6):1368–1374.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Fonseca R, Siegel D, et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016;128(9):1174–1180.
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115.
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394(10192):29–38.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2017;378:519–528.
   Web of Science ®Google Scholar
• Jasielec J, Dytfeld D, Griffith KA, et al. Minimal residual disease status predicts progression-free survival in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib, lenalidomide, and low-dose dexamethasone (KRd). Blood. 2014;124(21):2127–2127.
   Google Scholar
• Luoma S, Anttila P, Saily M, et al. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish myeloma group. Ann Hematol. 2019;98(12):2781–2792.
   PubMed Web of Science ®Google Scholar
• Dytfeld D, Jasielec J, Griffith KA, et al. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014;99(9):e162–e164.
   PubMed Web of Science ®Google Scholar
• van Vliet M, Jasielec J, Dytfeld D, et al. Prognostic and predictive gene expression profiling (GEP) markers confirmed in carfilzomib, lenalidomide, and dexamethasone (KRd) treated newly diagnosed multiple myeloma (NDMM) patients (pts). Blood. 2014;124(21):2141–2141.
   Google Scholar
• Costa LJ, Chhabra S, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based Dara-KRd consolidation in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2019;134(Supplement 1):860–860.
   PubMedGoogle Scholar
• Landgren O, Hultcrantz M, Diamond B, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. 2021;7(6):862.
   PubMed Web of Science ®Google Scholar
• Derman BA, Major A, Rosenblatt J, et al. A phase 2 study of extended daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. Blood. 2021;138(Supplement 1):2759–2759.
   Google Scholar
• Leypoldt LB, Besemer B, Asemissen AM, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2022;36(3):885–888.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320.
   PubMed Web of Science ®Google Scholar
• Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–527.
   PubMed Web of Science ®Google Scholar
• Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337–1345.
   PubMed Web of Science ®Google Scholar
• Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol. 2014;32(25):2712–2717.
   PubMed Web of Science ®Google Scholar